Nóos

Nóos has over two decades of experience developing scientifically validated supplements and medical devices for paediatric, respiratory, gastrointestinal, and general wellness. The company holds international patents for novel combinations such as resveratrol + carboxymethyl betaglucan. It has exclusive Italian rights to Biogaia AB's probiotic strain Lactobacillus reuteri DSM17938 under the Reuterin brand. In recent years, Nóos launched new formulations based on a patented Limosilactobacillus reuteri strain for gut and immune support.

Products are supported by clinical research; however, detailed results or published data are not specified on their public site.

ISO9001 certification attests to quality management standards.

Pipeline breadth includes several marketed brands/formulations plus ongoing R&D.

Key focus areas include paediatrics/neonatology, otolaryngology/ENT, gastroenterology/digestive health, allergology/allergy prevention/support.

Notable partnerships include an exclusive concession agreement with Biogaia AB for probiotics in Italy.